Sector: Health Care
Director information for EMERGENT BIOSOLUTIONS INC (data for year 2026)
| Name | Position | Age | Qualifications and Experience | Committee Memberships | Filing Year |
|---|---|---|---|---|---|
| Donald DeGolyer | Director | 64 | ["40 years of healthcare and corporate leadership experience", "Founder and Director of Vertice Pharma", "Chief Operating Officer of Endo International", "Chief Executive Officer of Sandoz Inc.", "Experience with Pfizer, Johnson & Johnson, and Novartis", "Board member of publicly traded companies HLS Therapeutics and TYME Technologies", "Non-profit board service including Make-a-Wish-NJ", "Founder of The Strong Women Foundation", "Executive M.B.A. from Harvard Business School", "M.B.A. from Fairleigh Dickinson University", "B.A. from University of Rochester"] | ["Compensation", "Quality, Compliance, Manufacturing and Risk Management"] | 2026 |
| John Fowler, Jr. | Director | 68 | ["over 30 years of healthcare and finance leadership experience", "chair of the board of trustees of the University of Virginia Darden School Foundation", "14 years at Wells Fargo Securities in senior leadership roles", "vice chairman, Corporate and Investment Banking at Wells Fargo", "positions as vice chairman of investment banking at Deutsche Bank", "head of Health Care Services Banking at JPMorgan", "head of Health Care Banking at Salomon Brothers", "president of Large Scale Biology Corporation", "founding partner of Bio-Strategic Directors", "managing partner of Baycrest Capital", "served on various corporate boards of directors"] | ["Audit and Finance"] | 2026 |
| Joseph C. Papa | President, CEO and director; Director, President & Chief Executive Officer; President, Chief Executive Officer and Director | 70 | ["over 35 years of experience in the healthcare and pharmaceutical industry", "Chief Executive Officer and Chairman at Bausch and Lomb Corporation", "Chairman and CEO of Bausch Health", "Chairman and CEO of Perrigo", "led the pharmaceutical and technologies services division at Cardinal Health", "President and Chief Operating Officer at Watson Pharmaceuticals", "worked for 14 years at Novartis Pharmaceuticals"] | [] | 2026 |
| Kathryn Zoon, Ph.D. | Director | 77 | ["NIAID/NIH Scientist Emeritus", "Member of the National Academy of Medicine since 2002", "Interim Director of the NIH Office of Research Support and Compliance", "Chief of the Cytokine Biology Section in the Division of Intramural Research, NIAID", "Chief of the Division of Cytokine Biology in CBER", "Ph.D. in biochemistry from Johns Hopkins University", "B.S. degree, cum laude, in chemistry from Rensselaer Polytechnic Institute", "President of the International Society for Interferon and Cytokine Research", "Served as Principal Deputy Director of the Center for Cancer Research at NCI", "Inducted into the Rensselaer Polytechnic Institute\u2019s Hall of Fame"] | ["Scientific Review (Chair)", "Nominating and Corporate Governance", "Quality, Compliance, Manufacturing and Risk Management"] | 2026 |
| Keith Katkin | Director | 54 | ["Chief Executive Officer of Urovant Sciences Ltd.", "President and Chief Executive Officer of Avanir Pharmaceuticals, Inc.", "Vice President, Commercial Development for Peninsula Pharmaceuticals, Inc.", "Chairman of Eledon Pharmaceuticals, Inc.", "Chairman of Ambros Therapeutics, Inc.", "M.B.A. from the Anderson School at UCLA", "B.S. in business and accounting from Indiana University", "Licensed Certified Public Accountant"] | ["Compensation", "Nominating and Corporate Governance"] | 2026 |
| Marvin White | Director; President and Chief Executive Officer | 64 | ["strong financial background", "tenure as Chief Executive Officer of Aptevo", "experience gained from senior positions he has held with other biopharmaceutical organizations"] | ["Audit and Finance (Chair)", "Scientific Review"] | 2026 |
| Neal Fowler | Director; Chief Executive Officer | 64 | ["strong background in biomedicines", "corporate finance", "tenure as Chief Executive Officer of Pathalys Pharma, Inc.", "experience gained from senior positions throughout his career"] | ["Audit and Finance", "Scientific Review"] | 2026 |
| Ronald Richard | Director | 70 | ["served as president and Chief Executive Officer of the Cleveland Foundation from June 2003 until August 2023", "president of Stem Cell Preservation, Inc.", "strategic business advisor for IGEN International, Inc.", "chief operating officer of In-Q-Tel", "various senior management positions at Panasonic", "former U.S. diplomat", "Chairman of the Board of Trustees of the International Biomedical Research Alliance", "trustee of the International Biomedical Research Alliance", "currently serves on the Boards of Trustees of University Hospitals, Case Western Reserve University and the Chautauqua Institution", "board of directors of Convelo and Astute Signals", "M.A. in international relations from Johns Hopkins University School of Advanced International Studies", "B.A. in history from Washington University", "honorary doctorates in humane letters from Notre Dame College and Baldwin Wallace College", "honorary doctorate in science from the Northeast Ohio Medical College"] | ["Nominating and Corporate Governance (Chair)", "Compensation"] | 2026 |
| Sujata Dayal | Director | 63 | ["vice president and global chief compliance officer of Medline Industries, Inc.", "expertise in transactional work, regulatory law, privacy and compliance", "previous vice president, healthcare compliance at Johnson & Johnson", "senior executive roles in ethics and compliance at Biomet, Inc. and Abbott Laboratories", "J.D. from Chicago-Kent College of Law", "LL.M. from Columbia University School of Law", "LL.B. from Rajasthan University Law School in Jaipur, India", "B.A. Honors degree in Political Science from Lady Shri Ram College in New Delhi, India"] | ["Audit and Finance", "Quality, Compliance, Manufacturing and Risk Management (Chair)"] | 2026 |
| Zsolt Harsanyi, Ph.D. | Director; Chairman of the Board | 82 | ["Chairman of the Board of N-Gene Research Laboratories, Inc.", "Chief Executive Officer and Chairman of the Board of Directors of Expo Bio Inc.", "Director of Aptevo Therapeutics Inc.", "President of Porton International plc", "Founder of Dynport Vaccine Company LLC", "Vice president of corporate finance at E.F. Hutton, Inc.", "Directed the first assessment of biotechnology for the U.S. Congress\u2019 Office of Technology Assessment", "Consultant to the Presidents\u2019 Commission for the Study of Ethical Problems in Medicine and Biomedical and Behavioral Research", "Faculty of Microbiology and Genetics at Cornell Medical College", "Ph.D. from Albert Einstein College of Medicine", "B.A. from Amherst College"] | ["Audit and Finance", "Scientific Review", "Quality, Compliance, Manufacturing and Risk Management"] | 2026 |
